GNLX Genelux Corporation
USHealthcareAs of 2026-10-08
Why GNLX matters now
Genelux Corporation (GNLX) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.50 with -0.79% on the session and $112.1M in market capitalization; recent performance reads 1-month +5.89% and YTD -32.00%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-7.1M, and EPS of $-0.22. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -25.0%.
The latest indexable market news headline is "Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $16.00; recent insider activity includes Smither John W filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.20
P/S
13941.77
EV/EBITDA
-3.27
DCF Value
$-0.01
FCF Yield
-25.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-3550.0%
Operating Margin
-422037.5%
Net Margin
-397225.0%
ROE
-165.2%
ROA
-98.2%
ROIC
-132.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-7.1M | $-0.22 |
| Q4 2025 | $8.0K | $-9.2M | $-0.25 |
| FY 2025 | $8.0K | $-32.1M | $-0.86 |
| Q3 2025 | $0.00 | $-8.0M | $-0.21 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.33
Target (Median)
$16.00
Target Range
$16.00 - $20.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.55
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.